BEAM

Announcements

Nothing here yet

Daily updates

• Beam Therapeutics sued two biotech companies, alleging that a former scientist stole confidential base-editing trade secrets and used them to establish a rival rare-disease program at YolTech Therapeutics. Serapha Bio, which licensed the therapy, denied the allegations.Oct 4, 2026

FDA designations

• Beam Therapeutics Receives FDA RMAT Designation for BEAM-101 in Sickle Cell DiseaseAug 14, 2025
• Beam Therapeutics Receives RMAT Designation for BEAM-302 Therapy for Alpha-1 Antitrypsin Deficiency (AATD)May 13, 2025

News

• Beam Therapeutics received FDA clearance of its IND application for BEAM-304 in phenylketonuriaJun 18, 2026
• Beam Therapeutics published Phase 1/2 BEACON data for risto-cel in sickle cell disease in NEJMApr 2, 2026
• Beam Therapeutics reported updated positive clinical data from its Phase 1/2 trial of BEAM-302 in AATD supporting advancementMar 25, 2026
• Beam Therapeutics announces U.S. FDA RMAT designation granted to BEAM-101 for treatment of sickle cell diseaseAug 14, 2025
• Beam reveals new Phase 1/2 BEACON trial data showing differentiated profile of BEAM-101 in sickle cell diseaseJun 16, 2025